Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections — De Clercq Erik (2017) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections
Shared by
De Clercq Erik
KU Leuven
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections
Article
2017
en
Related publications
Article
2020
Tenofovir at the Crossroad of the Therapy and Prophylaxis of HIV and HBV Infections
De Clercq Erik
Article
2016
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
De Clercq Erik
Letter
Authors
De Clercq Erik
KU Leuven
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
2006
The role of tenofovir in the prevention of HIV infections
De Clercq Erik
Article
2021
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections
De Clercq Erik
Article
2010
Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
De Clercq Erik
,
Geoffrey Férir
,
Suzanne J. F. Kaptein
,
Johan Neyts
Discussion(0)
No comments yet. Be the first to comment.